European Commission approves PONVORYTM ▼ (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features
Retrieved on:
Monday, May 24, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical devices, Clinical trials, Immunosuppressants, Medical specialties, Multiple sclerosis, Immunology, Medicine, Nitriles, Teriflunomide, Sphingosine-1-phosphate, Janssen Pharmaceuticals, Ponesimod, S1PR1, Sphingosine-1-phosphate receptor modulator, Multiple Sclerosis, PONVORY (ponesimod), the Janssen Pharmaceutical Companies of Johnson & Johnson, MULTIPLE SCLEROSIS, PONVORY (PONESIMOD), THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
Janssen Research & Development, LLC, and Johnson & Johnson Middle East FZ-LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Key Points:
- Janssen Research & Development, LLC, and Johnson & Johnson Middle East FZ-LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
- Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a Randomized clinical trial.
- Janssen Receives Positive CHMP Opinion for PONVORY (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features.
- 11 DAmbrosio D, Feedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.